Advanced Search


Study ID Status Title Patient Level Data
113038 Completed Monitoring of specific birth defects associated with exposure to Lamotrigine in pregnancy through the EUROCAT network
113043 Completed Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer’s disease or mild cognitive impairment Study Listed on
113045 Completed A Phase I Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 Pharmacokinetics and to Assess the Effect of GSK2248761 on CYP450 Probe Drugs in Healthy Adult Subjects
113046 Relinquished A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma.
113049 Completed A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy Study Listed on
113055 Completed Evaluation of GSK Biologicals’ Boostrix™ in healthy adults, 10 years after previous booster vaccination Study Listed on
113060 Completed Evaluation of GSK Biologicals’ Boostrix™ Polio in healthy adults, 10 years after a booster vaccination Study Listed on
113068 Completed Phase I, Open Label, Two Period Study to Evaluate the Effects of Fosamprenavir/Ritonavir on GSK1349572 Pharmacokinetics and a Phase I, Randomized, Three-Way Crossover Study to Evaluate the Relative Bioavailability of Three Tablet Variants made using Micronized, Unmicronized and Intermediate Particle Sizes of GSK1349572 in Healthy Adult Subjects
113073 Completed A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD Study Listed on
113074 Completed Value of Early 5-alpha-reductase Inhibitor (5ARI) Treatment in Patients Receiving Combination 5ARI and Alpha-Blocker (AB) Therapy for Enlarged Prostate (EP)
113077 Completed Efficacy, safety and immunogenicity study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 70 years or older Study Listed on
113078 Relinquished A Study to Evaluate Efficacy and Safety of Pazopanib versus Sunitinib for the Treatment of Asian Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma – A substudy to VEG108844
113079 Terminated Clinical evaluation of ropinirole IR (immediate release) tablets in patients who are diagnosed with symptomatic restless legs syndrome (RLS) associated with Chronic kidney disease (CKD) managed with haemodialysis (including haemofiltration and haemodiafiltration) Study Listed on
113086 Completed A randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects
113090 Completed A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthma Study Listed on
113091 Completed A randomised, double-blind, double-dummy, parallel-group multicentre study to assess efficacy and safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the treatment of persistent asthma in adults and adolescents Study Listed on
113092 Relinquished Drug Use Investigation for TYKERB tablet (All case investigation)
113094 Completed Observer-blind safety and immunogenicity study of GlaxoSmithKline Biologicals’ influenza vaccine GSK2186877A when administered to elderly subjects Study Listed on
113095 Completed Special Drug Use Investigation for ADOAIR DISKUS COPD (salmeterol and fluticasone)
113096 Completed An Open-Label, Single Sequence, Three-Period Drug Interaction Study of GSK1349572 and Tipranavir/Ritonavir in Healthy Adult Subjects (ING113096)
113097 Completed A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects (ING113097)
113099 Completed Phase 1, open label, two arm, fixed sequence study to evaluate the effect of rifampin and rifabutin on GSK1349572 pharmacokinetics in healthy male and female volunteers
113101 Relinquished A Phase IV study evaluating eltrombopag concentrations in breast milk of nursing mothers taking eltrombopag
113107 Completed A 12-week study to evaluate the 24 hour pulmonary function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) once daily compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on
113108 Completed A 24-week study to evaluate the effect of fluticasone furoate/vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.